reviewed april 2026|next review october 2026|88 physicians psi has verified|173 published studies
Thymosin Beta-10
Thymosin beta-10 is a 43-amino-acid naturally occurring (the body's own) actin-sequestering protein in the same family as thymosin beta-4, studied primarily as a cancer biomarker where its overexpression correlates with tumor aggressiveness and metastatic potential.
Evidence landscape: 173 published studies
173 published items. 9 human studies and 143 animal studies.
- 9 Human
- 143 Animal
- 21 Reviews
Not FDA-approved. Not in clinical development as a therapeutic. Thymosin beta-10 is studied as a cancer biomarker and cell biology research tool, not as a therapeutic agent.
Not available as a therapeutic product. Research-grade material available for laboratory use. The cancer biomarker association makes therapeutic development complicated.
Thymosin beta-10 is a naturally occurring (the body's own) 43-amino-acid actin-sequestering protein. It is in the same beta-thymosin family as thymosin beta-4 (the parent protein of TB-500). Both proteins compete for G-actin binding but appear to have distinct and sometimes opposing biological effects.
PSI Assessment
Within the beta-thymosin family, thymosin beta-4 is studied for tissue repair and regeneration. Its close relative thymosin beta-10 tells a different story: overexpression correlates with tumor aggressiveness and metastatic potential across multiple cancer types. Both proteins perform the same fundamental molecular function (sequestering G-actin monomers), but the biological outcomes appear to diverge in ways that researchers are still working to explain. The opposing-effects hypothesis suggests that the ratio between these two proteins may determine net cellular behavior. 173 published studies document the cancer biomarker and cell motility research. No therapeutic application for thymosin beta-10 has been developed.
Same family as thymosin beta-4 but studied primarily in cancer biology. Overexpression correlates with tumor aggressiveness. May have opposing effects to thymosin beta-4 in certain contexts.
The mechanism centers on G-actin sequestration, the same fundamental function as thymosin beta-4. Both proteins compete for G-actin binding, regulating the pool of monomeric actin available for cytoskeletal assembly. In cancer research, thymosin beta-10 overexpression correlates with increased cell motility, invasiveness, and angiogenesis in several tumor types, making it a potential biomarker for metastatic potential. The opposing-effects hypothesis suggests that the relative ratio of thymosin beta-10 to thymosin beta-4 may determine net cellular behavior.
What the evidence supports
Thymosin beta-10 overexpression correlates with tumor aggressiveness and metastatic potential across multiple cancer types, documented by independent research groups. The actin-sequestering mechanism is shared with thymosin beta-4 and well-characterized. 173 published studies focus on the cancer biomarker and cell motility research.
What is not yet established
Whether thymosin beta-10 is a driver or marker of tumor aggressiveness. Whether targeting thymosin beta-10 has therapeutic potential in cancer. The functional consequences of the thymosin beta-10 to beta-4 ratio in different tissue contexts. Whether the opposing-effects hypothesis between the two beta-thymosins is correct.
Research Evidence
The findings below cover the cancer biomarker research, the relationship to thymosin beta-4, and the actin dynamics that connect these two proteins.
Evidence by condition
Evidence dimensions available for each condition Thymosin Beta-10 has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cancer Biomarker Research | ||||
| Cell Motility/Invasion | ||||
| Actin Dynamics | ||||
| Angiogenesis |
Thymosin beta-10 overexpression correlates with tumor aggressiveness and metastatic potential across multiple cancer types, including colorectal, ovarian, and thyroid cancers.
These correlations have been documented by independent research groups, providing stronger evidence than single-laboratory findings. Whether thymosin beta-10 drives or merely marks tumor aggressiveness remains an open question.
9 Human|143 Animal|21 Reviews
View all 173 indexed studiesHow Thymosin Beta-10 Works
Thymosin beta-10 is a naturally occurring (the body's own) 43-amino-acid actin-sequestering protein. It competes with thymosin beta-4 for G-actin monomer binding, regulating the available pool of monomeric actin for cytoskeletal assembly. Overexpression correlates with cell motility, invasiveness, and angiogenesis in cancer contexts.
Like TB-500, it manages the cell skeleton by sequestering actin building blocks, but is studied primarily as a cancer biomarker where overexpression correlates with tumor aggressiveness.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
43-amino-acid actin-sequestering peptide. Competes with thymosin beta-4 for G-actin binding. Overexpressed in multiple cancer types with correlation to metastatic potential.
What is Thymosin Beta-10 being studied for?
Researchers are studying Thymosin Beta-10 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymosin Beta-10 overall. This means a compound can have human studies for one condition but only animal data for another.
Cancer Biomarker Research
·Animal StudiesThymosin beta-10 overexpression correlates with tumor aggressiveness and metastatic potential across multiple cancer types. Independent research groups have documented these associations in colorectal, ovarian, thyroid, and other cancers.
Limitations: Whether thymosin beta-10 is a causal driver or a correlative marker of tumor aggressiveness is not established. No therapeutic targeting strategy has been developed.
Cell Motility/Invasion
·Animal StudiesThymosin beta-10 regulates cell motility through actin cytoskeleton dynamics. Overexpression increases cell migration and invasiveness in laboratory models.
Limitations: The cell motility effects are characterized in vitro. Whether these effects are therapeutically targetable is unknown.
Actin Dynamics
·Animal StudiesThe G-actin sequestering mechanism is shared with thymosin beta-4 and well-characterized at the molecular level.
Limitations: How the competition between beta-10 and beta-4 for G-actin binding determines net cellular behavior in different tissue contexts is not fully resolved.
Angiogenesis
·PreclinicalThymosin beta-10 has context-dependent effects on angiogenesis (blood vessel formation), with both pro- and anti-angiogenic activity reported in different experimental systems.
Limitations: The context-dependent nature of the angiogenic effects makes biological interpretation difficult. No consistent pattern has been established across models.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. Studied as a cancer biomarker, not a therapeutic agent.
Availability: Not available as a therapeutic product. Research material only. The cancer association makes any supplementation approach a safety concern.
Class context: Thymosin beta-10 is a naturally occurring (the body's own) protein. The cancer biomarker association (overexpression correlating with tumor aggressiveness) raises fundamental questions about the safety of exogenous administration.
Thymosin beta-10 is a naturally occurring (the body's own) protein. The correlation between overexpression and tumor aggressiveness raises fundamental safety questions about any therapeutic or supplementation approach.
Questions and Comparisons
Questions the evidence raises for a Thymosin Beta-10 discussion.
Comparison and Related Research
Thymosin beta-10 is most meaningfully compared to its close relative thymosin beta-4 and the synthetic fragment TB-500.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A study demonstrating that suppressing thymosin beta-10 expression in cholangiocarcinoma cells increased migration and metastatic potential. The findings suggested thymosin beta-10 acts as a tumor suppressor in this cancer type by restraining cell motility through effects on actin dynamics.Sribenja S et al., 2013 in BMC Cancer. View on PubMed
- 2.Research showing that forced overexpression of thymosin beta-10 in human ovarian cancer cell lines disrupted the actin cytoskeleton and triggered programmed cell death. This was among the first studies to establish thymosin beta-10 as a potential mediator of apoptosis in cancer cells.Lee SH et al., 2001 in Oncogene. View on PubMed
- 3.A study identifying Ras signaling as a mechanistic target of thymosin beta-10. Overexpression of thymosin beta-10 inhibited both angiogenesis and tumor growth in animal models, and the authors demonstrated that this occurred through interference with Ras-mediated signaling pathways.Lee SH et al., 2005 in Cancer Res. View on PubMed
- 4.Through mutational analysis and computational modeling, this study identified specific amino acid residues in thymosin beta-10 that are critical for its pro-apoptotic activity. The work mapped the structural requirements for thymosin beta-10-mediated cell death induction.Rho SB et al., 2005 in J Biol Chem. View on PubMed
- 5.A comprehensive review of thymosin beta-10 research covering its differential expression across cancer types, the molecular mechanisms underlying its effects on cell migration and apoptosis, and its potential clinical significance as a biomarker and therapeutic target.Sribenja S et al., 2009 in Cancer Invest. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.